Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Common Share

Net Loss Per Common Share

9 Months Ended

Sep. 30, 2015

7. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period.

A calculation of basic and diluted net loss per common share follows:

	For the three months ended September 30,				For the nine months ended September 30,
($ in thousands except share and per share amounts)	2015		2014		2015		2014
Net loss attributable to common stockholders		(18,161)		(4,592)		(36,392)		(16,673)
Weighted average common shares outstandingbasic and diluted		39,412,056		36,024,810		39,038,522		35,977,355
Basic and diluted net loss per common share	$	(0.46)	$	(0.13)	$	(0.93)	$	(0.46)

Included in common stock issued and outstanding as of September 30, 2015 are 7,670,935 shares of unvested restricted stock, which are excluded from the weighted average common stock outstanding since its effect would be anti-dilutive.

The Company’s potential dilutive securities which consist of unvested restricted stock, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted net loss per share is the same.

The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive:

	For the three months ended				For the nine months ended
	September 30,				September 30,
	2015		2014		2015		2014
Warrants to purchase Common Stock		685,061		685,061		685,061		696,526
Options to purchase Common Stock		1,832,499		2,171,032		2,019,219		2,312,461
Unvested Restricted Stock		6,884,631		6,308,038		6,795,132		5,880,063
Unvested Restricted Stock Units		752,761		-		258,242		-
Total		10,154,952		9,164,131		9,757,654		8,889,050